VEGFA and hepatocellular carcinoma: Two phase II studies testing single agent bevacizumab therapy in unresectable HCC patients showed 13–14% ORRs, suggesting that VEGF is a valid target for HCC treatment (Siegel et al., 2008; Boige et al., 2012).